New drug could offer safer option after prostate cancer surgery

NCT ID NCT07711314

Recruiting now Disease control Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This trial tests whether the drug rezvilutamide, taken alone for 48 weeks after prostate removal surgery, can prevent cancer from coming back in men at high risk of recurrence. Standard treatment often includes long-term hormone therapy with significant side effects. The study aims to see if this single-drug approach is effective and better tolerated, potentially improving quality of life while keeping cancer at bay.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rezvilutamide tablets
What this could lead to: If successful, this could offer a new, less toxic treatment option for men at high risk of prostate cancer recurrence after surgery, potentially improving survival without the harsh side effects of standard hormone therapy.
What could go wrong: This is a small, early-phase study with no comparison group, so results may not be definitive. The drug may still cause side effects or fail to prevent cancer recurrence in some patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER (POST PROSTATECTOMY)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Nanjing Drum Tower Hospital, Affilitated Hospital of Medical School, Nanjing University
RECRUITING

Nanjing, Jiangsu, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.